Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Randomized Study of Efficacy and Safety of Testosterone in Metastatic Renal Cell Carcinoma Patients With Fatigue

Trial Profile

Phase 2 Randomized Study of Efficacy and Safety of Testosterone in Metastatic Renal Cell Carcinoma Patients With Fatigue

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Fatigue
  • Focus Therapeutic Use
  • Acronyms FARETES
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Primary endpoint has not been met. (Fatigue), as reported in an abstract presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Status changed from recruiting to completed, as reported in an abstract presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top